VANCOUVER, Canada

Kriti Singh

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kriti Singh: Innovator in Cancer Therapeutics

Introduction

Kriti Singh is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic compounds. Her work focuses on the Myc-Max inhibitory compounds, which hold promise for treating various types of cancer.

Latest Patents

Kriti Singh holds a patent for her invention titled "Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith." This patent describes Myc-Max inhibitory compounds that are designed to target and treat cancers such as prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma, and myeloid leukaemia. The patent highlights the structure of these compounds and their potential applications in cancer therapy. Kriti has 1 patent to her name.

Career Highlights

Kriti Singh is affiliated with the University of British Columbia, where she conducts her research. Her work has garnered attention for its potential impact on cancer treatment, showcasing her dedication to advancing medical science.

Collaborations

Kriti collaborates with esteemed colleagues, including Artem Tcherkassov and Paul S Rennie. These partnerships enhance her research efforts and contribute to the development of innovative cancer therapies.

Conclusion

Kriti Singh is a trailblazer in the field of cancer therapeutics, with her patented Myc-Max inhibitor compounds offering hope for effective cancer treatments. Her contributions to medical research are invaluable and continue to inspire advancements in cancer care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…